According to a recent LinkedIn post from Datavant, the company plans to participate in the upcoming ISPOR Annual meeting with a theater presentation on operationalizing lifecycle evidence for treatment utilization and outcomes insights. The session, scheduled for Tuesday, May 19, is set to feature moderator Ulka Campbell alongside contributors Ann Madsen and Batyrkhan Kuatov.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests the presentation will discuss study design for post-launch questions, endpoint and data source selection, and aligning evidence generation with market access, positioning, and performance monitoring. Datavant also highlights its presence at booth No. 617, emphasizing its role in supporting end-to-end evidence generation from early research through post-launch insights.
For investors, this activity indicates Datavant’s ongoing engagement with the health economics and outcomes research and real-world evidence communities. The focus on scalable data infrastructure and governance may underscore the company’s strategy to position its data connectivity and analytics capabilities as critical tools for life sciences customers seeking more timely and informed decision-making.
Participation in a specialized industry forum like ISPOR could help Datavant strengthen relationships with biopharma, HEOR, and RWE stakeholders, potentially supporting pipeline growth and customer retention. While the post is promotional in nature, it signals continued investment in thought leadership and product-relevant dialogue, which may contribute to Datavant’s competitive standing in the health data and life sciences evidence-generation market.